Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events Keiichi Yamanaka, MD, PhD, Hitoshi.

Alveolar nitric oxide and asthma control in mild untreated asthma

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Clarification concerning amoxicillin skin testing

Fatty acids, inflammation, and asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Atopic dermatitis: Age and race do matter!

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Patient perspectives on the management of atopic dermatitis

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants Christoph Grüber, MD, PhD, Margriet van.

Fatty acids, inflammation, and asthma

Practice Notes from the AAAI

Safety of allergen immunotherapy: A 10-year prospective study

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Katherine A. Vierk, MPH, Kathleen M. Koehler, PhD, MPH, Sara B

Yuichi Teraki, MD, Aika Sakurai, MD, Seiichi Izaki, MD

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

The National Biome Initiative: An allergy perspective

Nonadherence to Asthma Treatment: Getting Unstuck

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

News & Notes Journal of Allergy and Clinical Immunology

What are the best outcome measurements for atopic eczema

Atopic dermatitis: A practice parameter update 2012

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think Martin L. Moore, PhD, R.

Children's compliance with allergen immunotherapy according to administration routes Giovanni Battista Pajno, MD, Daniela Vita, MD, Lucia Caminiti, MD,

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Cephalosporin Side Chain Cross-reactivity

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,

Administration of Intravenous Immunoglobulin to a Patient with Hypogammaglobulinemia and Anti-IgA Antibodies Phillip Lieberman, MD, Rima Rachid, MD

Aaron M. Drucker, MD, Paula J. Harvey, PhD

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

New pathways for itching in patients with atopic dermatitis?

Risk of oral food challenges

The Editors' Choice Journal of Allergy and Clinical Immunology

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Reply Journal of Allergy and Clinical Immunology

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Severity assessment in asthma: An evolving concept

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

Kinase inhibitors in clinical practice: An expanding world

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Itching as a systemic disease

Presentation transcript:

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E. French, MD, Günther F.L. Hofbauer, MD Journal of Allergy and Clinical Immunology Volume 128, Issue 5, Pages 1128-1130 (November 2011) DOI: 10.1016/j.jaci.2011.09.009 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 A, Percentage of EASI scores over time, n = 3, 2-sided paired t test. B-D, EASI scores of patients over time: patient 1 (Fig 1, B), patient 2 (Fig 1, C), and patient 3 (Fig 1, D), with shaded boxes indicating treatment with tocilizumab and arrows indicating the administration of tocilizumab. E, Forearms of patient 2 over time, with relapse of clinical changes after missing 1 dose (compare with Fig 1, C). Journal of Allergy and Clinical Immunology 2011 128, 1128-1130DOI: (10.1016/j.jaci.2011.09.009) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions